Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 55154-7883

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 55154-7883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

D70042e0 D686 4ddc 9d54 C90a3f7f74b0 00

Donepezil Hydrochloride Tablets USP 10 mg label for a package containing 10 film-coated tablets. The label includes storage instructions, dosage reference to the product insert, and a pharmacist dispensing notice. Manufactured by Torrent Pharmaceuticals Ltd in India and distributed by Major Pharmaceuticals and Cardinal Health in the USA.*

FDA Label Image

D70042e0 D686 4ddc 9d54 C90a3f7f74b0 01

Donepezil Hydrochloride Tablets USP 5 mg film-coated tablets in a 10-tablet unit dose package. Label includes storage instructions, dosage reference, and warnings. Manufactured by Torrent Pharmaceuticals Ltd., India, distributed by Major Pharmaceuticals and Cardinal Health in the USA. The packaging is intended for institutional use only and is not child resistant.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 01

Chemical structure of Donepezil Hydrochloride depicted as a molecular formula diagram showing its aromatic rings, ether groups, piperidine ring, and hydrochloride component.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 02

A line graph showing ADAS-cog change from baseline (mean ± SE) over 30 weeks of treatment with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis represents weeks of drug treatment, and the y-axis shows cognitive change, with clinical improvement upward and clinical decline downward. Donepezil groups show clinical improvement, while placebo shows decline.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 03

A cumulative percentage curve chart comparing Donepezil Hydrochloride Tablets 5 mg/day and 10 mg/day to placebo in terms of change from baseline in cognitive scores (ADAS-cog). The x-axis shows change from baseline, and the y-axis shows cumulative percentage of patients. The chart includes data points for 7, 4, and no point change and a table showing percentage change in ADAS-cog scores for placebo, 5 mg/day, and 10 mg/day treatment groups.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 04

A bar chart displaying CIBIC-plus rating distribution for Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses compared to placebo. The chart shows percentages of patients across categories from markedly improved to markedly worse, illustrating patient response variability by treatment group.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 05

A line graph depicting the mean change from baseline in ADAS-cog scores over 15 weeks comparing Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo. The x-axis shows weeks of drug treatment, and the y-axis measures ADAS-cog change from baseline, with arrows indicating clinical improvement and decline. Donepezil treatment groups show greater clinical improvement than placebo.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 06

A cumulative percentage of patients chart depicting change from baseline in ADAS-cog scores for Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo. The graph shows three lines corresponding to each group, with vertical markers at -7, -4, and 0 points change, along with an inset table summarizing percentages of patients achieving these changes in ADAS-cog scores by treatment group.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 07

A bar graph displaying the percentage of patients by CIBIC-plus Rating, comparing Donepezil Hydrochloride Tablets at 10 mg/day, 5 mg/day, and placebo groups. The x-axis shows ratings from Markedly Improved to Markedly Worse, while the y-axis shows percentage of patients from 0 to 50. Different bars represent the three groups across each rating category.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 08

A line graph depicting SIB (Severe Impairment Battery) mean change from baseline over 6 months of treatment, comparing Donepezil Hydrochloride Tablets 10 mg/day to placebo. The vertical axis shows clinical improvement and decline, while the horizontal axis represents months of drug treatment. Donepezil shows increased clinical improvement over time compared to placebo, which indicates a decline.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 09

A cumulative percentage of patients graph comparing Donepezil Hydrochloride Tablets 10 mg/day with placebo. The x-axis shows SIB (Severe Impairment Battery) change from baseline, while the y-axis represents cumulative percentage of patients. The graph features two curves, one for donepezil (filled circles) and one for placebo (open squares), demonstrating the distribution of patient responses over a range of SIB changes.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 10

A line graph depicting the time course of change from baseline in ADCS-ADL-Severe scores over 6 months of treatment. It compares Donepezil Hydrochloride Tablets 10 mg/day to placebo, showing mean changes with standard error bars. The y-axis represents change from baseline, with higher values indicating clinical improvement and lower values clinical decline.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 11

A cumulative percentage curve graph comparing Donepezil Hydrochloride Tablets 10 mg/day and placebo groups. The X-axis represents ADCS-ADL change from baseline (negative values to the right), and the Y-axis shows the cumulative percentage of patients from 0 to 100%. Two lines depict patient distributions for Donepezil Hydrochloride (solid circles) and placebo (open squares).*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 12

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 13

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.